Showing results (181-190 of 219) with videos related to

Sort By:
Pageof 22
Neurologia|October 26, 2016
Experience with botulinum toxin in chronic migraineA Castrillo Sanz, N Morollón Sánchez-Mateos, C Simonet Hernández, et al.
Physics in Medicine and Biology|August 1, 2020
A new detector for the beam energy measurement in proton therapy: a feasibility studyA Vignati, S Giordanengo, F Mas Milian, et al.
Journal of Neurology|November 7, 2002
Antidisialosyl antibodies in chronic idiopathic ataxic neuropathyC Serrano-Munuera, R Rojas-García, E Gallardo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2013
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trialJ-Y Pierga, F-C Bidard, C Cropet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of diseaseG Curigliano, X Hu, R Dent, et al.
British Journal of Cancer|October 3, 1999
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)P Viens, T Palangié, M Janvier, et al.
Future Oncology (London, England)|July 8, 2020
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancerTomas Pascual, Juan M Cejalvo, Mafalda Oliveira, et al.
European Journal of Cancer (Oxford, England : 1990)|April 7, 2018
5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French studyA Ploquin, B Pistilli, E Tresch, et al.
NPJ Breast Cancer|May 29, 2026
Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial resultsMeritxell Bellet, Juan M Ferrero-Cafiero, Milana Bergamino Sirvén, et al.
British Journal of Cancer|February 5, 2009
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO groupI Ray-Coquard, B Weber, J Cretin, et al.
Pageof 22